Head-To-Head Review: THERAPIX BIOSCI/S (TRPX) and The Competition

Share on StockTwits

THERAPIX BIOSCI/S (NASDAQ: TRPX) is one of 526 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare THERAPIX BIOSCI/S to related companies based on the strength of its analyst recommendations, dividends, earnings, valuation, risk, profitability and institutional ownership.

Volatility & Risk

THERAPIX BIOSCI/S has a beta of -1.9, suggesting that its share price is 290% less volatile than the S&P 500. Comparatively, THERAPIX BIOSCI/S’s rivals have a beta of 1.17, suggesting that their average share price is 17% more volatile than the S&P 500.

Valuation & Earnings

This table compares THERAPIX BIOSCI/S and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
THERAPIX BIOSCI/S N/A -$6.24 million 3.92
THERAPIX BIOSCI/S Competitors $2.03 billion $140.19 million -2.13

THERAPIX BIOSCI/S’s rivals have higher revenue and earnings than THERAPIX BIOSCI/S. THERAPIX BIOSCI/S is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations and price targets for THERAPIX BIOSCI/S and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
THERAPIX BIOSCI/S Competitors 3726 10916 24876 815 2.56

As a group, “Pharmaceutical preparations” companies have a potential upside of 58.00%. Given THERAPIX BIOSCI/S’s rivals higher possible upside, analysts clearly believe THERAPIX BIOSCI/S has less favorable growth aspects than its rivals.


This table compares THERAPIX BIOSCI/S and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
THERAPIX BIOSCI/S N/A 33.18% 28.76%
THERAPIX BIOSCI/S Competitors -2,667.92% -76.75% -24.48%

Institutional and Insider Ownership

0.3% of THERAPIX BIOSCI/S shares are held by institutional investors. Comparatively, 46.8% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.0% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


THERAPIX BIOSCI/S rivals beat THERAPIX BIOSCI/S on 6 of the 10 factors compared.


Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110 for the treatment of Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for the treatment of Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. Therapix Biosciences Ltd. has a product development agreement with Cure Pharmaceutical to develop cannabinoid-based product for sleep disorders. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.

Receive News & Ratings for THERAPIX BIOSCI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for THERAPIX BIOSCI/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply